losartan/hct ranbaxy 50 mg/12,5 mg filmtabletten
basics gmbh - hydrochlorothiazid,losartan kalium - hydrochlorothiazid
losartan/hct ranbaxy 100 mg/25 mg filmtabletten
basics gmbh - hydrochlorothiazid,losartan kalium - hydrochlorothiazid
meropenem ranbaxy 500 mg pulver zur herstellung einer injektions- oder infusionslösung
basics gmbh - meropenem - meropenem
meropenem ranbaxy 1 g pulver zur herstellung einer injektions- oder infusionslösung
basics gmbh - meropenem - meropenem
esomeprazol ranbaxy 20 mg magensaftresistente tabletten
basics gmbh - esomeprazol magnesium - esomeprazol
esomeprazol ranbaxy 40 mg magensaftresistente tabletten
basics gmbh - esomeprazol magnesium - esomeprazol
confit - filmtabletten
ranbaxy (uk) ltd. - triamteren,verapamil hydrochlorid,hydrochlorothiazid - calcium channel blockers
ramipril "ranbaxy" 10 mg - filmtabletten
basics gmbh - ramipril - ace-inhibitors, plain
ramipril "ranbaxy" 5 mg - filmtabletten
basics gmbh - ramipril - ace-inhibitors, plain
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, typ 2 - drogen bei diabetes verwendet - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.